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With this article, the authors aim to honor the memory of Serafino Zappacosta, who
had been their mentor during the early years of their career in science. The authors
discuss how the combination of Serafino Zappacosta’s extraordinary commitment to
teaching and passion for science created a fostering educational environment that led
to the creation of the “Ruggero Ceppellini Advanced School of Immunology.” The review
also illustrates how the research on the MHC and the inspirational scientific context in the
Zappacosta’s laboratory influenced the authors’ early scientific interests, and subsequent
professional work as immunologists.
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Serafino Zappacosta, the founder of the “Ruggero Ceppellini Advanced School of Immunology”
(Ceppellini School), epitomized the term “mentor.” This term was first used by François Fénelon
in the book “Les Aventures de Télémaques” to define an enlightened educator who is endowed
with unprejudiced knowledge and wisdom (1). The name came after Mentor, the guardian and
educator of Odysseus’ son Telemachus who offered him encouragement and support for dealing
with personal dilemmas while his father was away fighting in the Trojan War. As a mentor
and professor of immunology at the University of Naples “Federico II,” Serafino Zappacosta
communicated science to his students and close collaborators as a fascinating tool to constantly
pursue and advance knowledge, thus nourishing their innate human eagerness to learn. The authors
of this article had the privilege to be former members of Zappacosta’s laboratory, and wish to offer
him this posthumous tribute.
Serafino Zappacosta was a highly cultivated scientist, whose interests spanned from the classics
to arts (2). His open-minded vision led him to go beyond the traditional approach to didactics
toward newmodels of education. He conceptualized the idea of an international advanced school of
immunology because of his recognition of the quintessential importance in committing educational
efforts to nurturing generations of young researchers from all over the world, promoting exchanges
between western world and developing countries. The Zappacosta’s school model embraced an
open and transparent communication that was instrumental to expand the creative potential of
independent-minded young investigators, to foster their critical and analytical interests, and to
channel their energies into highly valuable scientific directions.
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Serafino Zappacosta founded the Ceppellini School in 1991
together with Antonio Di Giacomo (Experimental Immunologist
working at the Monaldi Hospital in Naples, Italy), Melchiorre
Brai (Professor of Immunology at the University of Palermo,
Italy), Giovan Battista Ferrara (Professor of Human Genetics
at the Federico II University of Naples, Italy), Albert Nisonoff
(Professor of Biology at Brandeis University, in Waltham,
Massachusetts, USA), and Ciro Manzo (Head of Immunology
Department at the Istituto Pascale in Naples, Italy). The choice of
Naples as Ceppellini School headquarters was no accident. This
city had experienced in 1799, during the Neapolitan Republic,
an unsuccessful attempt to gain freedom from the constraints
of a tyrannical monarchy, and to promote a new political
organization. This attempt was brutally suppressed. The choice
of Naples symbolically reflected the will to propel the freedom of
scientific minds according to the School’s motto “non multa sed
multum” (“not many but much,” i.e., quality rather than quantity)
(3). Over the years, the Ceppellini School has been attracting and
engaging large numbers of international young scientists to the
field of immunology.
FOCUSING ON MHC MOLECULES
Serafino Zappacosta had a strong interest in the major
histocompatibility complex (MHC) genes and proteins. He
shared his fascination for the MHCwith his laboratory members,
with whom he investigated a variety of topics in the MHC
field, including the regulation of HLA expression in tumor
cells (4, 5), the association between HLA alleles and diseases
in Southern Italy (6, 7), the influences of MHC class I (MHC-
I) on tumor killing by NK cells (8), and the cytokine-mediated
regulation of MHC-I expression (9). His laboratory also worked
in collaboration with many international teams to study HLA
polymorphisms, and participated in collaborative workshops on
HLA typing, that included the International Histocompatibility
Workshop in 1991 in Yokohama, Japan (10). This interest in
MHC also led to the name of the Ceppellini School, after
the immuno-geneticist Ruggero Ceppellini, who had greatly
contributed with his pioneer work to the understanding of the
genetic bases of HLA polymorphisms, and coined the term
“haplotype” (11).
MHC POLYMORPHISM AND THE
MEDITERRANEAN AREA
Before molecular genetics could rely on modern technology
to collect a tremendous amount of information, many data
about the genetic background of different human populations
were based on the analysis of products of polymorphic loci
including HLA. Analyzing the HLA system at the end of
the ‘70s, Zappacosta, together with Mario De Felice, Michele
Fiore and Giovan Battista Ferrara (12), found significant
differences between people living in Northern Italy and
the population of Campania (in Southern Italy). Significant
similarities were noticed between Mediterranean and Middle
Eastern populations and people from Campania, confirming
that the genetic background of the Italian population is
highly mixed. Furthermore, a peculiar association between
HLA alleles and congenital adrenal hyperplasia was found
by Serafino Zappacosta, Michele Maio, Mario De Felice and
Rossella Valentino in the Sothern Italian population (6). These
studies were performed at the time when Luigi Cavalli-Sforza
investigated the selection of advantageous alleles in HLA locus
and other polymorphic loci, whereby those findings served to
illustrate migration patterns of human populations (13).
Further studies on MHC polymorphism were performed over
the years by Giuseppina Ruggiero, Giuseppe Matarese, Giuseppe
Terrazzano, and others in the Zappacosta’s laboratory. They
demonstrated a link between HLA alleles and susceptibility to
autoimmune/infectious diseases in Southern Italy (7, 14). Other
Zappacosta’s team members, including Michele Maio, Luigi Del
Vecchio, and Mario De Felice, documented the association
between HLA-DR alleles and thyroid carcinoma (15). In the 80’,
Michele Maio, Luigi Del Vecchio, Giuseppina Ruggiero, Mario
De Felice and others of the Zappacosta’s laboratory investigated
MHC-I expression as a prognostic factor in breast cancer (5).
Antonio Pinto, Michele Maio and others showed that HLA-
DR expression by myeloid leukemia cells was modulated by
anti-neoplastic drugs (4).
MHC MOLECULES AND THE REGULATION
OF NK CELL RESPONSE
In the late ’80, Silvia Fontana, Luigi Racioppi and Ennio Carbone
in Zappacosta’s team investigated the link between retroviral
infection and MHC-I expression by tumor cells, using virus-
induced rat thyroid adenocarcinomas as an experimental model
(16, 17). At the time, state-of-the-art techniques for these studies
included tissue culture, microscopy, immunofluorescence, and
cytofluorimetry, that had only become available a few years
earlier. Silvia Fontana, Ennio Carbone, and others in the team
showed that tumor transformationmodulatedMHC-I expression
by rat tumor cells, and that rat Large Granular Lymphocytes
(LGL) killed more effectively tumor cells having low MHC-I
expression (8). These observations were puzzling at that time.
In 1987—just a few years before these studies—, Bjorkman and
colleagues had solved the HLA A2 crystallographic structure (18,
19), and a lot of attention was concentrated on the TCR/MHC-
I molecular interaction, and its role in immunity. On the other
hand, Ennio Carbone of the Zappacosta’s team was fascinated by
pioneering studies on the inhibitory signals provided by MHC-
I to Natural Killer (NK) cells [the “missing self ” hypothesis,
formulated by Klas Karre in 1981 (20)]. Together with Antonio
La Cava, Giuseppe Terrazzano and others, the Zappacosta
group’s contributions to the NK field spanned from MHC-I
mediated regulation of NK cell cytotoxicity in rat tumor models
(8, 21), to NK cell inhibition induced by soluble HLA-I (22),
to new findings on the role of NK cells in human tumor
immunosurveillance (23), NK/ dendritic cells cross-talk (24, 25),
and CD1-mediated inhibition of NK cytotoxicity (26). Giuseppe
Terrazzano in the group investigated the effects of IL-10 on
MHC-I expression and on the antigen presenting machinery
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(9), demonstrating a pathological role of gliadin in the NK cell/
dendritic cells cross-talk (27). Sadly, this publication was the last
one that included Serafino Zappacosta’s co-authorship.
MHC MOLECULES AND THE REGULATION
OF T CELL RESPONSE
In the early 90’s, it was well-established that the function of
MHC molecules was to bind and present antigenic peptides to
T cells (28, 29). The molecular bases of this phenomenon had
been largely resolved by several independent studies (30–35).
However, looking out of this canonical box, it was possible to
hypothesize that, in addition to binding TCR and CD4, MHC
class II (MHC-II) molecules might also interact with other cell
surface molecules, and in turn regulate the activation of immune
cells. Within this context, Zappacosta’s group aimed to identify
non-canonical functions of HLA-II molecules (36–39). A large
panel of monoclonal antibodies (mAbs) directed against different
epitopes of HLA-II molecules provided by Soldano Ferrone
(40) were instrumental for these studies, that were performed
in in vitro models of polyclonal T-cell proliferation, induced
by either phytohemoagglutinin (PHA) or anti-CD3 mAb (41,
42). Although the presence of antigen presenting cells (APC)
was required to achieve full T-cell activation, HLA-II antigen
presenting function was largely dispensable in these models,
thus offering a unique opportunity to evaluate non-canonical
functions of HLA-II molecules.
Giuseppina Ruggiero and Luigi Racioppi in Zappacosta’s
team, in collaboration with Ciro Manzo, initiated these pioneer
studies on HLA-II molecules, and demonstrated that the
incubation of autologous monocyte-derived macrophages with
mAbs directed against non-polymorphic determinants of HLA-
II molecules exerted a remarkable inhibitory effect on T cell
activation (37, 38, 43). This result suggested that MHC-II
molecules expressed on the APC could interact not only with the
TCR and CD4, but also with additional ligand(s)—at the time
unknown—, expressed on the T cell surface. Interestingly, in 1996
one of these hypothetical ligand was identified by Huard et al.
(44), who demonstrated the ability of CD223 (aka LAG-3) to bind
MHC-IImolecules. In the last two decades, the relevance of LAG-
3/MHC-II signaling has been confirmed by several independent
studies, being this molecular interaction involved in a variety of
immuno-regulatory circuits (45).
D’Oro and Di Rosa from the Zappacosta’s team further
explored non-canonical functions of MHC-II molecules
expressed by activated human T cells. These studies were
based on the general hypothesis that HLA-II molecules might
transduce intracellular signals, and in turn finely tune T cell
response to antigen(s) and cytokines. The results confirmed
this possibility, showing that cross-linking of HLA-II on
activated T cells was sufficient to induce inositol triphosphates
(IP3) accumulation, protein kinase C (PKC) activation, and,
ultimately, enhanced T cell proliferation (10, 39). Of note, the
ability of MHC-II molecules to transduce intracellular signals
has also been recognized in B cells (46–48), and more recently a
cell-intrinsic contribution of MHC-II expression has been shown
in the B cell development in the bone marrow (49).
As a note, the findings by Zappacosta’s group on non-
canonical functions of the HLAmolecules have relevant, and still
largely unexplored, implications in the regulation of the human
immune response. For example, high expression of LAG-3 by T
regulatory (Treg) cells suggests that LAG-3/MHC-II complexes
might play an important role in the bi-directional signaling
triggered by Treg/ T effector cell interactions (50, 51). In this
sense, an increasing number of studies has pointed to LAG-
3/MHC-II interaction as an attractive druggable target to treat
autoimmune diseases, stimulate anti-cancer immune response
(52), and revert resistance to anti-PD-1 immunotherapy (53).
MHC AND BEYOND
Giuseppe Matarese devoted his experimental efforts on the
innovative hypothesis that nutrient-energy-sensing pathways
might represent a powerful tool to control immunological self-
tolerance. He showed that leptin, a hormone critically involved
in energy balance and body weight regulation, acts as a strong
immune-modulator, that influences the susceptibility to infection
and autoimmunity (54, 55). Leptin levels inversely correlated
with regulatory T cell number in multiple sclerosis patients (56),
and a direct link between leptin and regulatory T cell anergy was
established (57). This observation, that was further developed
in subsequent studies performed by Giuseppe Matarese and his
group, in collaboration with Antonio La Cava, was the result
of frequent, endless, unforgettable evening lab discussions with
Serafino Zappacosta.
After training with Serafino Zappacosta with a focus on
the immune-modulating properties of MHC molecules, the
team members subsequently developed new hypotheses and
investigations in diverse directions, ranging from the study
of the fundamental mechanisms of immune regulation
and immunological memory, to autoimmunity, cancer
immunotherapy and vaccinology (58–66). Serafino Zappacosta
kept to enthusiastically follow the progress of the past members
of his team after they left to start their independent careers.
Many of them remained involved over the years in the Ceppellini
School activities, either as faculty members or as components
of the board of directors, maintaining the School as an arena of
continuous scientific education and dynamic discussion.
CONCLUSIONS
The review summarizes the legacy left by Serafino Zappacosta
to his collaborators who, albeit with different individual
perspectives and at a different degree, continued to work
on the MHC, looking at these molecules as a window of
opportunity to comprehend the complexity of the immune
response, rather than merely looking at them as antigen
presenting molecules.
After the death of Serafino Zappacosta in 2006, Silvia
Fontana became the President of the Ceppellini School,
and Ennio Carbone, Giuseppe Matarese, Francesca Di Rosa,
Giuseppina Ruggiero, Giuseppe Terrazzano and other previous
collaborators of the Zappacosta’s team continued to organize
advanced international immunology courses, together with the
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long-standing Serafino Zappacosta’s collaborators and friends
Antonio Di Giacomo, who co-founded the School in 1991
(3), Elizabeth Simpson, who organized the first Ceppellini
School Course in 1992 on bone marrow transplantation (67),
and the newly recruited Ceppellini School Scientific Director
Stefan Kaufmann (68). A new type of event, the Serafino
Zappacosta Memorial Conferences, was initiated in 2007. Since
2010, this event has been held in the newly inaugurated
“Serafino Zappacosta” Auditorium of the Federico II University
of Naples. All these activities were made possible by the
excellent work of the Ceppellini School Scientific Secretary
Tricia Reynolds.
To conclude, the continuation of the activities of the
Ceppellini School not only allows an unceasing engagement of
new young bright minds to the fascinating field of immunology,
but also keeps alive Serafino Zappacosta’s dream that intellectual
freedom can be shared without boundaries for the benefit of
younger generations.
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DEDICATION
This article is dedicated to the memory of Luigi Del Vecchio,
past member of Zappacosta’s team and full professor of Clinical
Biochemistry and Molecular Biology, Dipartimento di Medicina
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